Advances in 17-allylamino-17-demethoxygeldanamycin
- VernacularTitle:17-丙烯胺基-17-去甲氧基格尔德霉素研究进展
- Author:
xin-yu, JIANG
;
dao-zhen, CHEN
- Publication Type:Journal Article
- Keywords:
Neoplasms;
Drug therapy
- From:
Journal of International Oncology
2006;0(09):-
- CountryChina
- Language:Chinese
-
Abstract:
17-allylamino-17-demethoxygeldanamycin (17-AAG) is a heat shock protein 90 ( HSP90) inhibitor. It is capable of target-inhibiting tumor-derived HSP90, leading to the depletion of on-cogenic client proteins which play key roles in several signal transduction pathways. Then cell growth and differetiation are inhibited. 17-AAG results in cytostasis and apoptosis. A lot of trials have indicated that 17-AAG is a selective target drug for cancer therapy. It can efficiently inhibit multiple signal transduction pathways involved in tumor cell proliferation and survival. Clinical phaseⅠand phaseⅡtrials have shown that 17-AAG has good pharmacokinetic-pharmacodynamic profile. Moreover, it can combine with radiation and the traditional chemotherapeutics and increase the therapeutic efficacy.
